Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Mitsuhiro TakenoHiroaki DobashiYoshiya TanakaHajime KonoShouji SugiiMitsumasa KishimotoSue ChengShannon McCueMaria ParisMindy ChenYoshiaki IshigatsuboPublished in: Modern rheumatology (2021)
Apremilast reduced the number of oral ulcers and overall disease activity in this Japanese subgroup with Behçet's syndrome.